期刊文献+

重组人白细胞介素12对健康人外周血单个核细胞产生γ干扰素影响的研究 被引量:1

Study on the influence of recombinant human interleukin-12 inducing the interferon-γ production of PBMC from healthy subjects
暂未订购
导出
摘要 目的建立重组人白细胞介素12(rhIL-12)的生物活性检测方法,观察rhIL-12诱导健康人外周血单个核细胞(PBMC)产生γ干扰素(IFN-γ)的水平与剂量和时间之间的关系,揭示其变化规律。方法rhIL-12供试品刺激健康人PBMC分泌IFN-γ,经国际标准品校正,建立rhIL-12生物活性测定方法。以1 ng/mL浓度rhIL-12诱导健康人PBMC,分别于24、48、72、96和120 h 5个时间点用酶联免疫吸附试验(ELISA)测定培养上清的IFN-γ水平。测定0.1、0.5和2.5 ng/mL 3个浓度rhIL-12诱导人PBMC 72 h后培养上清的IFN-γ水平,用Prism 5.0统计软件的重复测量方差分析法对所得数据进行统计学处理。结果rhIL-12供试品的生物活性曲线呈典型S型,IFN-γ含量为最大浓度一半时的供试品浓度(ED50)为(1.008±0.238)ng/mL,供试品rhIL-12效价为7 938 IU/mL。测定1ng/mL浓度rhIL-12刺激健康人PBMC后5个时间点培养上清中IFN-γ显示,不同个体高峰出现时间有所不同,在高峰出现前均呈现递增趋势。高、中、低3个浓度rhIL-12分别诱导健康人PBMC产生的IFN-γ水平与浓度之间呈显著量效关系,且在0.1 ng/mL的极低浓度即可诱生高水平IFN-γ。结论rhIL-12供试品生物活性良好,与国际标准品比对基本一致,不同人群对rhIL-12的应答高峰存在个体差异,以诱生IFN-γ作为评价rhIL-12生物活性的指标具有明显的量效关系。 Objective To establish a method for detecting hioactivity of recombinant human interleukin-12 (rhiL- 12) in order to observe the relationship between induction dose/time and the level of interferon-γ (IFN-γ) in the trials of peripheral blood mononuclear cells ( PBMC ) from heahhy subjects which were induced by rhIL-12, and reveal the change rules. Methods The tested rhIL-12 was used for stimulating PBMC from healthy subjects to produce IFN-γ. The method for detecting rhiL-12 bioactivity was established after calibrating by international standard rhIL-12. The IFN- γ levels in culture supernatant of PBMC from healthy subjects which were stimulated by 1 ng/mL rhIL-12 at 5 time points of 24, 48, 72, 96 and 120 h were analyzed by enzyme-linked immunosorbent assay (ELISA). The IFN-γ levels in culture supernatant of PBMC in response to 0. 1 , 0.5 and 2.5 ng/mL rhiL-12 72 h stimulation were determined, respectively. The statistical analysis of data were performed by one-way analysis of variance with Prism 5.0. Results An S-curve of tested rhiL-12 bioactivity could achieve. 50% effective dose (ED50) was (1. 008 ±0.238) ng/mL, and the potency of tested rhlL-12 was 7 938 IU/mL. The IFN-3, levels detected in culture supernatant of PBMC from healthy subjects in response to 1 ng/mL rhIL-12 stimulation at 5 time points indicated that IFN-γ peak values in different subjects showed up at varied times with increasing tendency before the summit forming. There was a significant dose- effect correlation between IFN-γ production of PBMC from healthy subjects and the high dose, middle dose and low dose of rhIL-12. Furthermore, a very low dose of 0. 1 ng/mL also could induce high IFN-γ level. Conclusions The bioactivity of tested rhIL-12 is good, which is almost identical with that of international standard rhIL-12. There are individual variations among different people in response to rhlL-12 stimulation and there is a significant dose-effect correlation, evaluating the bioactivity index of rhIL-12 with induced IFN-γ.
出处 《检验医学》 CAS 北大核心 2009年第8期586-590,共5页 Laboratory Medicine
关键词 重组人白细胞介素12 Γ干扰素 细胞免疫 Interleukin-12, human,recombinant Interferon-γ Immunity, cellular
  • 相关文献

参考文献15

  • 1Murphy KM, Ouyang W, Farrar JD, et al. Signaling and transcription in T helper development [ J ]. Annu Rev Immunol, 2000, 18(3) :451-494.
  • 2Mavropoulos A, Sully G, Cope AP, et al. Stabilization of IFN-gamma mRNA by MAPK p38 in IL-12- and IL-18-stimulated human NK cells [ J]. Blood, 2005, 105( 1 ) :282-288.
  • 3王威,饶春明,王军志.重组人白介素-12生物学活性检测方法的建立[J].中国生物制品学杂志,2006,19(5):514-515. 被引量:5
  • 4Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells [ J]. J Immunol, 1991, 146(9) :3074-3081.
  • 5Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity [ J ]. Nat Rev Immunol, 2003, 3 (2) : 133-146.
  • 6Orleans-Lindsay JK, Deru A, Craig JI, et al. In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic ceils; a strategy for ex-vivo generation of CTL for immunotherapy [ J]. Clin Exp Immunol, 2003, 133(13) :467-475.
  • 7Valenzuela J, Schmidt C, Mescher M. The rules of IL- 12 in providing a third signal for clone expansion of naive CD8^ + T cells [ J]. J Immunol, 2002, 169 (12) :6842-6849.
  • 8Weiss JM,Subleski JJ ,Wigginton JM ,et al. Immunotherapy of cancer by IL-12-based cytokine combinations[ J]. Expert Opin Biol Ther, 2007, 7( 11 ) :1705-1721.
  • 9Del Vecchio M, Bajetta E, Canova S,et al. Interleukin- 12: biological properties and clinical application [ J ]. Clin Cancer Res, 2007, 13 (16) :46774685.
  • 10Kim M. Cytokine therapy in cancer [J]. Expert Opin on Biol Ther, 2008, 8(10) :1495-1505.

二级参考文献7

共引文献4

同被引文献5

  • 1Del Vecchio M, Bajetta E, Canova S, et al. Interleukin12: biological properties and clinical application[J]. Clin CancerRes,2007,13(16) :4 677.
  • 2Portielje JE, Kruit WH, Schuler M, et al. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer[J]. Clin Cancer Res, 1999,5 ( 12 ) : 3 983.
  • 3Dawson PJ. Effect of formulation and freeze-drying on the long-term stability of rDNA-derived cytokines[J]. Dev Biol Stand, 1992,74: 273.
  • 4Souilae PO, Middaugh CR, Rytting JH. Investigation of protein/carbohydrate interactions in the dried state. 2. Diffuse reflectance FTIR studies[J]. Int J Pharm, 2002, 235 (1-2):207.
  • 5Wu SL, Leung D, Tretyakov L, et al. The formulation and mechanism of multimerization in a freeze-dried peptide[J], lnt JPharm, 2000,200( 1 ) : 1.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部